Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)
AURORA, ON, Jan. 30 /PRNewswire-FirstCall/ - Helix BioPharma Corp. announces that at the Company's Annual General Meeting held on January 29th, 2008, shareholders adopted all of the resolutions presented by management, appointing KPMG LLP as auditor, electing Don Segal, John Docherty, Ken Cawkell, Jack Kay, Slawomir Majewski, and Gordon Lickrish as directors, and approving certain amendments to the Company's by-laws.
Joining the Helix BioPharma board is Professor Slawomir Majewski, Head of the Department of Dermatology and Venereology at the Warsaw School of Medicine in Poland. Professor Majewski's extensive experience in the field of dermatology, and especially sexually transmitted diseases and skin cancer, will be of great benefit to the Board of Directors and the senior management team at Helix.
Retiring from Helix's board are Conor Gunne and Dr. Richard Rossman, who served as directors of Helix for a number of years. "I would like to personally thank both Conor and Richard for their valuable contribution to the Company over the many years and wish them both well in their other endeavors," said Don Segal, CEO of Helix BioPharma.
Helix's management would also like to thank its shareholders for their continued support, and looks forward to the further development of the Company's new drug products, Topical Interferon Alpha-2b and L-DOS47, in the year ahead.
A Report of Voting Results in respect of the Meeting will be posted on the SEDAR website at (http://www.sedar.com).
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in
the field of cancer therapy. The company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives include
its Topical Interferon A
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved